Efficacy and Safety of GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis

Repurposing glucagon‐like peptide‐1 (GLP‐1) and GIP/GLP‐1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects and reductions in cerebrospinal fluid secretion and intracranial pressure in vivo.

• Publication year

  2025

• Venue

  European Journal of Neurology

• Publication date

  2025-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ene.70358PMID 40937960PMCID 12426903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension.

  2025cited by this paper
• A randomized sequential cross‐over trial evaluating five purportedly ICP‐lowering drugs in idiopathic intracranial hypertension

  2025cited by this paper
• GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation

  2024cited by this paper
• Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis

  2024cited by this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review

  2024cited by this paper
• Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis

  2024cited by this paper
• Changes in Prevalence of Idiopathic Intracranial Hypertension in the United States Between 2015 and 2022, Stratified by Sex, Race, and Ethnicity

  2024influential reference
• Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension

  2024cited by this paper
• Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis

  2024cited by this paper
• A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis

  2023cited by this paper
• Weight Management Interventions for Adults With Idiopathic Intracranial Hypertension

  2023cited by this paper
• Transorbital sonography in idiopathic intracranial hypertension: Single‐center study, systematic review and meta‐analysis

  2023cited by this paper
• Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension

  2023influential reference
• The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

  2023influential reference
• Telltale Signs of Idiopathic Intracranial Hypertension With Normal Opening Cerebrospinal Fluid Pressure

  2022cited by this paper
• The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes

  2022cited by this paper
• Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta−analysis

  2022cited by this paper
• Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension

  2021cited by this paper
• Optic disc drusen mimicking Idiopathic Intracranial Hypertension (IIH): rely on ultrasound

  2021cited by this paper
• Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT)

  2021cited by this paper
• Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines

  2021cited by this paper
• The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis.

  2021cited by this paper
• Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension

  2019cited by this paper
• RoB 2: a revised tool for assessing risk of bias in randomised trials

  2019cited by this paper
• Analysing data and undertaking meta‐analyses

  2019influential reference
• Meta‐analysis and systematic review of population‐based epidemiological studies in idiopathic intracranial hypertension

  2018cited by this paper
• [Image Findings in Spontaneous Intracranial Hypotension (SIH)].

  2018cited by this paper
• Advances in the understanding of headache in idiopathic intracranial hypertension

  2018cited by this paper
• European Headache Federation guideline on idiopathic intracranial hypertension

  2018cited by this paper
• Idiopathic intracranial hypertension: consensus guidelines on management

  2018cited by this paper
• Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

  2017cited by this paper
• A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

  2017cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• Interventions for idiopathic intracranial hypertension.

  2015cited by this paper
• European Guidelines for Obesity Management in Adults

  2015cited by this paper
• Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

  2014cited by this paper
• Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

  2014cited by this paper
• Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children

  2014cited by this paper
• Epidemiology and Risk Factors for Idiopathic Intracranial Hypertension

  2014cited by this paper
• Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children

  2013cited by this paper
• Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study

  2010cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Interventions for idiopathic intracranial hypertension.

  2005cited by this paper
• Statistical Power Analysis for the Behavioral Sciences

  1969influential reference
• Transformations Related to the Angular and the Square Root

  1950cited by this paper
• Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension A Population Study

  year unknowncited by this paper

• Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis.

  2026cites this paper
• Novel use of GLP-1 receptor agonist therapy for pediatric idiopathic intracranial hypertension: a case report.

  2026cites this paper
• Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

  2025cites this paper
• Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis

  2025cites this paper
• Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.

  2025cites this paper